We seek to gain insight into the potential long term clinical outcomes of SBRT for prostate cancer by comparing PSA kinetics (nadir and slope) in patients treated with SBRT with those of patients treated with CF-EBRT. This evidence concerns the gene KLK3 and prostate cancer.